FOLH1 and prostate carcinoma: Piflufolastat F-18 (PylarifyTM) (Figure 10) was approved for positron emission tomography (PET) imaging as a radioactive diagnostic agent of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer.